1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Θετικών Επιστημών
  4. Τμήμα Χημείας
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/10404
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaougos, V. G.en
dc.contributor.authorTambaki, A. P.en
dc.contributor.authorKalogirou, M.en
dc.contributor.authorKostapanos, M.en
dc.contributor.authorGazi, I. F.en
dc.contributor.authorWolfert, R. L.en
dc.contributor.authorElisaf, M.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:56:13Z-
dc.date.available2015-11-24T16:56:13Z-
dc.identifier.issn1079-5642-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/10404-
dc.rightsDefault Licence-
dc.subjecthyperlipidemiaen
dc.subjectlipoproteinsen
dc.subjectpaf-acetylhydrolaseen
dc.subjectlp-pla(2)en
dc.subjectezetimibeen
dc.subjectfenofibrateen
dc.subjectrosuvastatinen
dc.subjectactivating-factor-acetylhydrolaseen
dc.subjectlow-density-lipoproteinen
dc.subjectcholesterol absorption inhibitoren
dc.subjectb-containing lipoproteinsen
dc.subjectpaf-acetylhydrolaseen
dc.subjecthuman plasmaen
dc.subjectendothelial dysfunctionen
dc.subjectldlen
dc.subjectlysophosphatidylcholineen
dc.subjectdiseaseen
dc.titleDifferential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A(2)en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDoi 10.1161/Atvbaha.107.147280-
heal.identifier.secondary<Go to ISI>://000249587000024-
heal.identifier.secondaryhttp://atvb.ahajournals.org/content/27/10/2236.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2007-
heal.abstractObjective-Lipoprotein- associated phospholipase A(2) (Lp-PLA(2)) is a predictor for incident atherosclerotic disease. We investigated the effect of 3 hypolipidemic drugs that exert their action through different mechanisms on plasma and lipoprotein-associated Lp-PLA(2) activity and mass. Methods and Results-In 50 patients with Type IIA dyslipidemia were administered rosuvastatin (10 mg daily), whereas in 50 Type IIA dyslipidemic patients exhibiting intolerance to previous statin therapy were administered ezetimibe as monotherapy (10 mg daily). Fifty patients with Type IV dyslipidemia were given micronised fenofibrate (200 mg daily). Low- and high-density lipoprotein (LDL and HDL, respectively) subclass analysis was performed electrophoretically, whereas lipoprotein subfractions were isolated by ultracentrifugation. Ezetimibe reduced plasma Lp-PLA(2) activity and mass attributable to the reduction in plasma levels of all LDL subfractions. Rosuvastatin reduced enzyme activity and mass because of the decrease in plasma levels of all LDL subfractions and especially the Lp-PLA(2) on dense LDL subfraction (LDL-5). Fenofibrate preferentially reduced the Lp-PLA(2) activity and mass associated with the VLDL+IDL and LDL-5 subfractions. Among studied drugs only fenofibrate increased HDL-associated Lp-PLA(2) (HDL-Lp-PLA(2)) activity and mass attributable to a preferential increase in Lp-PLA(2) associated with the HDL-3c subfraction. Conclusion-Ezetimibe, rosuvastatin, and fenofibrate reduce Lp-PLA(2) activity and mass associated with the atherogenic apoB-lipoproteins. Furthermore, fenofibrate improves the enzyme specific activity on apoB-lipoproteins and induces the HDL-Lp-PLA(2). The clinical implications of these effects remain to be established.en
heal.publisherAmerican Heart Association, Inc.en
heal.journalNameArteriosclerosis Thrombosis and Vascular Biologyen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Show simple item record
Files in This Item:
File Description SizeFormat 
Saougos-2007-Differential effect.pdf613.37 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons